Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ISIS-3521.

K Li1, J Zhang, P Sirois

  • 1Drew Medical Center, CA 90059, USA. kali@cdrewu.edu

Current Opinion in Molecular Therapeutics
|November 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Superantigen reactivity of gamma delta T cell clones isolated from patients with multiple sclerosis and controls.

Cellular immunology·1995
Same author

Tissue distribution of cocaine methyl esterase and ethyl transferase activities: correlation with carboxylesterase protein.

The Journal of pharmacology and experimental therapeutics·1995
Same author

Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E.

The American journal of pathology·1995
Same author

Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter.

Molecular and cellular biology·1995
Same author

A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity.

Nature genetics·1995
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Antisense oligonucleotides (AS ONs) show promise for cancer therapy by selectively inhibiting Protein Kinase C-alpha (PKC-alpha). Early clinical trials indicate good tolerance, with ongoing evaluation for efficacy in cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protein Kinase C (PKC) enzymes are crucial for intracellular signaling and implicated in various diseases, including cancer.
  • Limited isozyme specificity of traditional PKC antagonists hinders clinical application.
  • PKC-alpha isozyme is specifically linked to the proliferation of several cancer cell types.

Purpose of the Study:

  • To explore the potential of antisense oligonucleotides (AS ONs) as selective inhibitors of PKC isozymes for cancer therapy.
  • To investigate the efficacy and safety of AS ONs targeting PKC-alpha.

Main Methods:

  • Development of AS ONs targeting specific PKC-alpha mRNA.
  • Testing AS ON efficacy in cell cultures and animal cancer models.
  • Conducting Phase I clinical trials to assess safety and tolerability.

Related Experiment Videos

Main Results:

  • AS ONs demonstrate high selectivity for PKC isozymes, even within closely related gene families.
  • Positive results observed in preclinical cancer models (cell culture and xenografts).
  • Phase I clinical trials showed AS ONs were well-tolerated at high doses with minimal side effects.

Conclusions:

  • AS ONs targeting PKC-alpha represent a promising strategy for cancer treatment due to their specificity.
  • Further clinical evaluation is necessary to determine the therapeutic benefit of AS ONs in cancer patients, alone or in combination therapy.